TrialHaematologica2024

Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.

Shinya Rai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.